American Oncology Network, LLC — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$444,154	21
2024	Research	$14,195	5
2023	Research	$42,163	23
2022	Research	$129,545	38
2021	Research	$19,520	6
2020	Research	$4,781	1

Breakdown

Who paid Research payments · program years 2020–2025

AstraZeneca Pharmaceuticals LP $410,861 26 payments
Seattle Genetics, Inc. $125,817 60 payments
AstraZeneca UK Limited $55,663 2 payments
Celgene Corporation $48,830 3 payments
E.R. Squibb & Sons, L.L.C. $8,686 1 payment
Alexion Pharmaceuticals, Inc. $4,500 2 payments

Studies the money was for Research payments · program years 2020–2025

An Open-label, Phase 2 Basket Study of SEA-CD40 Combination Therapies in Advanced Malignancies $125,817 60 payments
A Phase III, double-blind, placebo-controlled, Randomized, Multicenter, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients With Locally Advanced Stage III, Unresectable Non-small Cell Lung Cancer NSCLC $74,012 2 payments
a phase 3 multi center,open label,sponsor blinded,randomized study of azd0901 monotherapy compared with investigator s choice of therapy in second or later line adult participants with advanced metastatic gastric or gastroesophageal junction adenocarcinoma expressing claudin18 2 $66,292 1 payment
CAMBRIA-1 A Phase III, Open-Label,Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2 $66,004 1 payment
Prospective, Open-Label, Single-Arm, Phase II Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL (ACRUE) $54,007 1 payment
Connect MDS/AML - Connect Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry: The purpose of the Connect Myeloid disease registry is to provide unique insights into treatment decisions and tr $45,830 2 payments
A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination with Durvalumab and Carboplatin Versus Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Locally Advanced or Metastatic NSCLC without Actionable Genomic Alterations (D926NC00001; AVANZAR) $45,664 3 payments
A Randomized 2-cohort Double-blind Placebo-controlled Phase III Study of AZD5305 in Combination with Physicians Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer EvoPAR-Prostate01 $37,443 1 payment
a phase III,two arm,parallel,randomized,multi center,open label,global study to determine the efficacy of volrustomig,plus chemotherapy versus pembrolizumab plus chemotherapy for first line treatment of patients with metastatic non small cell lung cancer $37,028 2 payments
A Phase III, Open-label, Randomized Study of Osimertinib with or without Datopotamab deruxtecan (Dato-DXd), as First-line Treatment in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer $35,050 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.